RESEARCH MONOGRAPH · KDC-MN-119

PQQ (Pyrroloquinoline Quinone)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

66/100

Bacterial redox cofactor with interesting mitochondrial biogenesis story and thin human trial base

PQQ is one of those molecules where the mechanism story is more compelling than the clinical evidence. It's a redox-active orthoquinone first identified as a bacterial cofactor for various quinoprotein dehydrogenases (methanol dehydrogenase being the original example), present in trace amounts in human dietary intake from plant and microbial sources, and proposed as a possible vitamin candidate (though the "vitamin" claim has been argued back and forth and isn't settled).

The interesting biology centers on mitochondrial biogenesis. The Chowanadisai 2010 work showed PQQ in cell culture and animals induced PGC-1α expression, which is the master regulator of mitochondrial biogenesis, with downstream NRF1/NRF2 activation and increases in mitochondrial mass. That's a real and replicated finding in cell models and rodents. The mechanism connects through CREB phosphorylation and probably involves the redox cycling capability of PQQ as a signal-rather-than-bulk-antioxidant.

The human trial base is thin. Nakano 2009 and others have done small Japanese trials showing some effects on subjective sleep and stress measures and inflammatory markers, plus a handful of small cognitive endpoint trials with mixed results. Effect sizes are typically modest and the trials are typically small. The mitochondrial biogenesis endpoint hasn't been well-tested in humans with proper biomarkers.

What we like: a real, identified mechanism (PGC-1α / mitochondrial biogenesis) that's mechanistically distinct from the typical "antioxidant" story. Most antioxidants don't drive transcriptional mitochondrial responses, PQQ at least plausibly does. The molecule itself is well-characterized and stable.

What we dont like is the gap between the mechanism story and the human trial base. The supplement industry has marketed PQQ on the mitochondrial biogenesis claim quite heavily, while the human evidence that PQQ at oral doses actually drives that response in vivo is much thinner than the marketing suggests. The bioavailability and tissue distribution of oral PQQ in humans aren't fully characterized.

Sourcing: PQQ disodium salt (the most stable form) is available as research-grade material at HPLC 98%+ purity. Cost has come down significantly as Chinese fermentation production scaled up over the last decade. Quality is now reasonable from reputable suppliers. The molecule is moderately hygroscopic but otherwise stable.

Interesting biology, undertested in humans, defensible as a research compound at the mechanism level, less defensible as a clinical-application claim. Worth knowing about, treat the marketing skeptically.

Evidence: 50
Mechanism: 70
Reliability: 55
Safety: 85
Sourcing: 78
Value: 65
Signal: 62
Staying power: 62

Plain-language summary Intrigue 60 / 100

PQQ (pyrroloquinoline quinone) is a redox cofactor found in plants and bacteria that may stimulate mitochondrial biogenesis (creation of new mitochondria). Sold as a longevity and energy supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Redox cofactor

A bacterial redox cofactor and putative mitochondrial biogenesis enhancer found in trace amounts in plant foods, sold as a dietary supplement.

Abstract

Pyrroloquinoline quinone (PQQ; CAS 72909-34-3; molecular formula C14H6N2O8; molecular weight 330.21) is a redox cofactor present in bacterial dehydrogenases and in trace amounts in plant foods (kiwi, parsley, green tea, fermented soy). PQQ has been studied as a putative mitochondrial biogenesis stimulant; chronic dietary PQQ deficiency in mice produces mitochondrial dysfunction phenotypes that are reversed by repletion. The compound has been studied for cognitive function, fatigue, and cardiovascular endpoints in small human trials with modest effect sizes. Mechanism is incompletely characterized; proposed activities include direct redox cycling, NRF2 pathway activation, and PGC-1alpha-mediated mitochondrial biogenesis. Reported research dose ranges in the literature span 10 to 40 mg. The compound is sold as a dietary supplement (BioPQQ).

Mechanism of action

Redox cofactor; NRF2 pathway activation; PGC-1alpha-mediated mitochondrial biogenesis (proposed).

Reported research dose ranges

Reported research dose ranges in the literature: 10 to 40 mg.

References

Stites T, et al. Pyrroloquinoline quinone modulates mitochondrial quantity and function. J Nutr 2006.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-119

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

PQQ (Pyrroloquinoline Quinone)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs